Recombinant FOLR1 (Mirvetuximab Biosimilar) 抗体
Quick Overview for Recombinant FOLR1 (Mirvetuximab Biosimilar) 抗体 (ABIN7581416)
抗原
抗体类型
适用
宿主
克隆类型
标记
应用范围
-
-
Expression System
- CHO Cells
-
原理
- Anti-FOLR1 / FRA Reference Antibody (mirvetuximab)
-
序列
- QVQLVQSGAE VVKPGASVKI SCKASGYTFT GYFMNWVKQS PGQSLEWIGR IHPYDGDTFY NQKFQGKATL TVDKSSNTAH MELLSLTSED FAVYYCTRYD GSRAMDYWGQ GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG,DIVLTQSPLS LAVSLGQPAI ISCKASQSVS FAGTSLMHWY HQKPGQQPRL LIYRASNLEA GVPDRFSGSG SKTDFTLTIS PVEAEDAATY YCQQSREYPY TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
-
产品特性
- Anti-FOLR1 Reference Antibody (mirvetuximab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.2 kDa.
-
纯度
- >95 %
-
亚型
- IgG1
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
说明
-
Therapeutic Agents by Target and Mechanism: FOLR1 antagonist
Conditions: Ovarian Cancer
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
浓度
- 1 mg/mL
-
缓冲液
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
储存条件
- 4 °C,-80 °C
-
储存方法
- +4°C,-80°C
-
-
- FOLR1 (Mirvetuximab Biosimilar)
-
物质类
- Biosimilar
-
背景
- Synonyms: FOLR1, Folate receptor 1
-
分子量
- 145.2 kDa
-
UniProt
- P15328
抗原
-